This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AstraZeneca should face new trial in Nexium case, drug buyers tell appeals court

By Richard Vanderford ( October 5, 2016, 21:35 GMT | Insight) -- ​An appeals court should reopen a so-called pay-for-delay lawsuit over AstraZeneca's alleged efforts to thwart generic competition to its heartburn drug Nexium, drug buyers argued, saying the trial judge stopped a jury from hearing crucial evidence. The three-judge panel that heard the appeal didn't give a clear indication of their thinking.An appeals court should reopen a so-called pay-for-delay lawsuit over AstraZeneca's alleged efforts to thwart generic competition to its heartburn drug Nexium, drug buyers argued Wednesday, saying the trial judge stopped a jury from hearing crucial evidence....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections